ArticleDiscover oncology2025
Causal relationship between blood metal levels and breast cancer risk: a Mendelian randomization study in East Asian populations.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectStudies in European populations have shown an association between blood metal levels and cancer risk. This study aimed to investigate the causal relationship between breast cancer (BC) risk and blood metal levels in East Asian populations using Mendelian randomization (MR).
methodsThe BC outcome data were obtained from the Biobank Japan database (2020), encompassing 95,283 East Asian women, including 5,552 cases of BC and 89,731 controls. BC was classified according to the ICD-10 code C509 (malignant neoplasm of the breast, unspecified). Exposure data regarding blood metal levels were obtained from a genome-wide association study (GWAS) involving the Chinese population conducted in 2022. In this study, the levels of 21 metals in serum and plasma were evaluated using inductively coupled plasma mass spectrometry (ICP-MS). MR analyses employed five methods: inverse variance weighted (IVW), contamination mixture (CM), mendelian randomization and robust adjusted profile score (MR-RAPS), debiased inverse variance weighted (dIVW), and constrained maximum likelihood and Model Average (cML-MA). Furthermore, we performed heterogeneity and horizontal pleiotropy assessments on the study results to evaluate their robustness.
resultsPlasma lead levels were robustly and positively associated with BC risk. IVW model [OR = 1.154, 95%CI: 1.062-1.255, P = 0.001, P-FDR = 0.030]. No significant heterogeneity (Cochran's Q: P = 0.832), pleiotropy (MR-Egger intercept: P = 0.799) and reverse causality were found. Other blood metal levels (aluminum, arsenic, barium, calcium, cadmium, cobalt, chromium, copper, iron, magnesium, manganese, molybdenum, nickel, rubidium, selenium, tin, strontium, titanium, vanadium, zinc) were not significantly associated with BC (P > 0.05).
conclusionElevated plasma lead levels are a significant risk factor for BC in East Asian populations, offering valuable insights into the prevention of BC.
Indexed as
Identifiers
41296249What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.